IFCC committee on markers for bone turnover and bone disease - Project presentation

被引:0
作者
Woloszczuk, W
机构
关键词
UNDERCARBOXYLATED OSTEOCALCIN; SERUM;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
In 1995 a proposal to establish a Committee on Bone Markers was presented to the Scientific Division of the International Federation of Clinical Chemistry. Following the Terms of Reference that were adopted by the Committee two tasks were selected as the first focus: To establish sources for reference materials for two of the many potential analytes of bone metabolism, namely pyridinoline/desoxypyridinoline and osteocalcin. Details on the first of these analytes were presented in a previous paper [1]. In this presentation, the steps to establish a reference material for osteocalcin are outlined. Due to the immunoheterogeneity of circulating osteocalcin the epitope specificity of antibodies used in immunoassays determines the values measured. Different degrees of carboxylation at the three gamma-carboxy-glutamic acid residues not only influence crossreactivity in assay systems but also represent biological functionality. Stability of osteocalcin and the effect of preanalytical steps has been described as problematic and depending on assay characteristics. After the characterisation and selection of reference preparations for osteocalcin, their performance in immunoassays, but also the clinical value in terms of clinical usefulness should be evaluated. Eventually, the standardization should further the comparability of measurements and promote the appropriate and rational use of biochemical markers of bone turnover.
引用
收藏
页码:95 / 99
页数:5
相关论文
共 11 条
[1]   BONE GLA PROTEIN (OSTEOCALCIN) ASSAY STANDARDIZATION REPORT [J].
DELMAS, PD ;
CHRISTIANSEN, C ;
MANN, KG ;
PRICE, PA .
JOURNAL OF BONE AND MINERAL RESEARCH, 1990, 5 (01) :5-11
[2]  
GARNERO P, 1994, J BONE MINER RES, V9, P225
[3]  
Hertz HS, 1995, EUR J CLIN CHEM CLIN, V33, P999
[4]   OSTEOCALCIN - A NONINVASIVE INDEX OF METABOLIC BONE-DISEASE IN PATIENTS TREATED BY CAPD [J].
JOFFE, P ;
HEAF, JG ;
HYLDSTRUP, L .
KIDNEY INTERNATIONAL, 1994, 46 (03) :838-846
[5]   SERUM PROPEPTIDE AND INTACT MOLECULAR OSTEOCALCIN IN NORMAL-CHILDREN AND CHILDREN WITH GROWTH-HORMONE (GH) DEFICIENCY - A POTENTIAL MARKER OF BONE-GROWTH AND RESPONSE TO GH THERAPY [J].
KANZAKI, S ;
HOSODA, K ;
MORIWAKE, T ;
TANAKA, H ;
KUBO, T ;
INOUE, M ;
HIGUCHI, J ;
YAMAJI, T ;
SEINO, Y .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (04) :1104-1109
[6]  
KENT N, 1997, SCAND J CLIN LA S227, V57, P73
[7]   DECREASED SERUM OSTEOCALCIN LEVELS IN PHENPROCOUMON-TREATED PATIENTS [J].
PIETSCHMANN, P ;
WOLOSZCZUK, W ;
PANZER, S ;
KYRLE, P ;
SMOLEN, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (05) :1071-1074
[8]  
Robins SP, 1996, CLIN CHEM, V42, P1621
[9]  
SOKOLL LJ, 1995, CLIN CHEM, V41, P1121
[10]   SERUM UNDERCARBOXYLATED OSTEOCALCIN IS A MARKER OF THE RISK OF HIP FRACTURE IN ELDERLY WOMEN [J].
SZULC, P ;
CHAPUY, MC ;
MEUNIER, PJ ;
DELMAS, PD .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1769-1774